<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03292861</url>
  </required_header>
  <id_info>
    <org_study_id>ATG Pilot Study</org_study_id>
    <nct_id>NCT03292861</nct_id>
  </id_info>
  <brief_title>The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients</brief_title>
  <official_title>A Pilot Randomized Study to Assess the Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients: A 12-month, Single Center, Randomized, Open-label Study of Efficacy Comparing Immediate Treatment With and Without Thymoglobulin® 1.5 mg/kg/d for 5 Consecutive Days in Heart Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, controlled, single center study to evaluate the efficacy of&#xD;
      Thymoglobulin induction therapy in combination with Mycophenolate Mofetil, tacrolimus, and&#xD;
      steroids in the prevention of CAV. Approximately half of the patients will be randomized to&#xD;
      receive a total of 5 doses of Thymoglobulin during the study. The first dose of Thymoglobulin&#xD;
      will be administered at 1.5 mg/kg via intravenous infusion over 6 hours immediately upon&#xD;
      arrival to the ICU post-operation (day 1). Subsequent doses of 1.5 mg/kg will be administered&#xD;
      on days 2, 3, 4, and 5 via IV infusion over 4 hours.&#xD;
&#xD;
      Mechanistic assays (T-reg cells, Lym subsets, B cell subsets, IL-1b, cytokines, TGFb, IL-21&#xD;
      to be drawn at Pre-transplant, 3, 6, 12 months post-transplant) will also be performed.&#xD;
&#xD;
      All patients will be followed and monitored according to standard of care protocols for heart&#xD;
      transplant recipients at our center.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">September 13, 2018</start_date>
  <completion_date type="Anticipated">October 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Composite Efficacy Failure at 12 Months</measure>
    <time_frame>12 Months</time_frame>
    <description>Composite efficacy failure is defined as development of de novo donor specific antibodies (measured by standardized alloantibody testing by Luminex and control sera, characterizing kinetics, specificities and relative binding strength) and ischemia on endomyocardial biopsy (characterized on biopsy by myocyte necrosis and/or regions of myocyte dropout) at 12 months post-transplant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in immune cell profiles</measure>
    <time_frame>12 months</time_frame>
    <description>Correlations between significant changes in immune cell profiles and biomarkers, and their relation to any significant differences in clinical outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in biomarkers</measure>
    <time_frame>12 months</time_frame>
    <description>Correlations between significant changes in biomarkers and their relation to any significant differences in clinical outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who experience rejection</measure>
    <time_frame>12 months</time_frame>
    <description>Number of patients who experience acute cellular, antibody-mediated, hemodynamic compromise, and any-treated rejection within first 12 months after transplantation/</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of episodes per patient</measure>
    <time_frame>12 months</time_frame>
    <description>Number of acute cellular, antibody-mediated, hemodynamic compromise and any-treated rejection episodes per patient within the first 12 months post-transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First rejection by ISHLT biopsy grading scale</measure>
    <time_frame>12 months</time_frame>
    <description>First acute cellular, antibody-mediated, hemodynamic compromise, and any-treated rejection by the ISHLT biopsy grading scale in the first 12 months post-transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first rejection</measure>
    <time_frame>12 months</time_frame>
    <description>Time to first acute cellular, antibody-mediated, hemodynamic compromise, and any-treated rejection within the first 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of primary graft dysfunction (PGD)</measure>
    <time_frame>first 24 hours post-transplant</time_frame>
    <description>The incidence of Primary Graft Dysfunction(PGD) in the first 24 hours post-transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient and graft survival</measure>
    <time_frame>12 months</time_frame>
    <description>Patient and graft survival at 12 months post-transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Types of patients with fatal infectious complications</measure>
    <time_frame>12 months</time_frame>
    <description>The types of patients with fatal infectious complications (especially CMV infection) within the first 12 months post-transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with fatal infectious complications</measure>
    <time_frame>12 months</time_frame>
    <description>The number of patients with fatal infectious complications (especially CMV infection) within the first 12 months post-transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Types of patients with non-fatal infectious complications</measure>
    <time_frame>12 months</time_frame>
    <description>Types of patients with non-fatal infectious complications (especially CMV infection) within the first 12 months post-transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with non-fatal infectious complications</measure>
    <time_frame>12 months</time_frame>
    <description>Number of patients with non-fatal infectious complications (especially CMV infection) within the first 12 months post-transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from development of circulating antibodies</measure>
    <time_frame>12 months</time_frame>
    <description>Freedom from the development of circulating antibodies within the first 12 months post transplantation, where circulating antibodies include donor specific antibodies (DSA), non-specific antibodies, and non-human leukocyte antigen antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in coronary maximal intimal thickness</measure>
    <time_frame>12 months</time_frame>
    <description>Change in coronary maximal intimal thickness at matched sites by intravascular ultrasound at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in coronary intimal area</measure>
    <time_frame>12 months</time_frame>
    <description>Change in coronary intimal area at matched sites by intravascular ultrasound at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in coronary intimal volume</measure>
    <time_frame>12 months</time_frame>
    <description>Change in coronary intimal volume at matched sites by intravascular ultrasound at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in coronary vessel area</measure>
    <time_frame>12 months</time_frame>
    <description>Change in coronary vessel area at matched sites by intravascular ultrasound at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in coronary intimal index</measure>
    <time_frame>12 months</time_frame>
    <description>Change in coronary intimal index at matched sites by intravascular ultrasound at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in coronary percent atheroma volume</measure>
    <time_frame>12 months</time_frame>
    <description>Change in coronary percent atheroma volume at matched sites by intravascular ultrasound at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance doses of mycophenolate mofetil, tacrolimus, sirolimus, and dose of corticosteroids</measure>
    <time_frame>12 months</time_frame>
    <description>Maintenance doses of mycophenolate mofetil, tacrolimus, sirolimus, and cumulative dose of corticosteroids at 12 months post-transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospital days per patient</measure>
    <time_frame>3 months, 6 months, 12 months</time_frame>
    <description>Number of hospital days per patient, both during the transplant period and during the post-transplant period at 3 months, 6 months, and 1 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients requiring hospitalization</measure>
    <time_frame>3 months, 6 months, 12 months</time_frame>
    <description>Number of patients requiring hospitalization by 3 months, by 6 months, or by 1 year post-transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death/Re-transplant</measure>
    <time_frame>12 months</time_frame>
    <description>To describe between treatment groups the incidence of the composite primary endpoint of death/re-transplant at 12 months post-transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic compromise rejection</measure>
    <time_frame>12 months</time_frame>
    <description>To describe between treatment groups the incidence of the composite primary endpoint of hemodynamic compromise rejection at 12 months post-transplantation. This is an ejection fraction of ≤ 30% or a 0.20 absolute decrease from baseline, and the need for inotropic agents OR a fractional shortening ≤ 20% or a 25% decrease from baseline, and the need for inotropic agents PLUS need for inotropic agents due to a Cardiac Index (CI) &lt; 2.0 L/min/m2 or a 25% decrease from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft dysfunction</measure>
    <time_frame>12 months</time_frame>
    <description>To describe between treatment groups the incidence of the composite primary endpoint of graft dysfunction (ejection fraction less than or equal to 40% by echocardiography)at 12 months post-transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cellular rejection</measure>
    <time_frame>12 months</time_frame>
    <description>To describe between treatment groups the incidence of the composite primary endpoint of biopsy proven cellular rejection ≥2R at 12 months post-transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody mediated rejected</measure>
    <time_frame>12 months</time_frame>
    <description>To describe between treatment groups the incidence of the composite primary endpoint of biopsy proven antibody mediated rejection ≥AMR1 at 12 months post-transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Allograft Vasculopathy (CAV)</measure>
    <time_frame>12 months</time_frame>
    <description>To describe between treatment groups the incidence of cardiac allograft vasculopathy (CAV) (defined as a change ≥0.5mm in maximal intimal thickness (MIT) of the coronary arteries by intravascular ultrasound at 12 months as compared to baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any treated rejection</measure>
    <time_frame>12 months</time_frame>
    <description>To describe between treatment groups any treated rejection at 12 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Heart Transplantation</condition>
  <arm_group>
    <arm_group_label>Thymoglobulin®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Thymoglobulin® (Genzyme) [rabbit anti-thymocyte globulin (ATG)] is a purified pasteurized, gamma immune globulin, obtained by immunization of rabbits with human thymocytes. This immunosuppressive product contains polyclonal cytotoxic antibodies directed against antigens expressed on human T-lymphocytes. Approximately half of the patients will be randomized to receive a total of 5 doses of Thymoglobulin during the study. The first dose of Thymoglobulin will be administered at 1.5 mg/kg via intravenous infusion over 6 hours immediately upon arrival to the ICU post-operation (day 1). Subsequent doses of 1.5 mg/kg will be administered on days 2, 3, 4, and 5 via IV infusion over 4 hours.&#xD;
In addition, there will be maintenance doses of mycophenolate mofetil, tacrolimus, sirolimus, and cumulative dose of corticosteroids at 12 months post-transplantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No induction therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients qualifying for the study will be randomized before the transplantation surgery in a 1:1 ratio to either Thymoglobulin® or no treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymoglobulin</intervention_name>
    <description>Approximately half of the patients will be randomized to receive a total of 5 doses of Thymoglobulin during the study. The first dose of Thymoglobulin will be administered at 1.5 mg/kg via intravenous infusion over 8 hours immediately upon arrival to the ICU post-operation (day 1). Subsequent doses of 1.5 mg/kg will be administered on days 2, 3, 4, and 5 via IV infusion over 4-8 hours.</description>
    <arm_group_label>Thymoglobulin®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>3.0 grams divided bid begun post-transplant, either IV or po as tolerated by patient. Initial dose must be given within 24 hours post-transplant. Dosing will be titrated based on recipient's body size and any adverse side effects</description>
    <arm_group_label>Thymoglobulin®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Doses of 1-4 mg bid either IV or po will be prescribed to achieve a target trough level of 10-15 ng/mL before post-operative day number 5. Target trough levels are 10-15 ng/mL for post-operative days #1-30, 8-12ng/mL days#31-60 and 5-10 ng/mL thereafter.</description>
    <arm_group_label>Thymoglobulin®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Maintenance doses of sirolimus at 12 months post-transplantation</description>
    <arm_group_label>Thymoglobulin®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Corticosteroids</intervention_name>
    <description>125 mg IV methylprednisolone immediately post-operatively x 3 doses q12hrs, then switching to oral prednisone at 1.0 mg/kg/day po divided into bid doses that are rounded off to the next higher 5 mg increment. For example, a 76 kg person would should be dosed at 38 mg po bid, which rounded off to the next 5 mg increment would be 40 mg po bid. (Equivalent dosing via an alternative route may be used if pos not tolerated or contraindicated). Prednisone will be tapered by 10 mg qd until the dose of 10 mg po bid is reached.</description>
    <arm_group_label>Thymoglobulin®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Study Entry:&#xD;
&#xD;
          1. Subjects must be undergoing their first allograft transplant&#xD;
&#xD;
          2. Men and non-pregnant women must be 18 to 70 years old&#xD;
&#xD;
          3. Women of childbearing potential must have a negative serum pregnancy test within 7&#xD;
             days prior to transplantation. The sensitivity must be equal to at least 50 mIU/mL.&#xD;
             (Urine test is allowed in addition to serum test in patients where serum results are&#xD;
             delayed)&#xD;
&#xD;
          4. Men with a female partner of child bearing age and women of childbearing potential&#xD;
             must use two reliable forms of contraception simultaneously. Effective contraception&#xD;
             must be used before beginning study drug therapy, and for 4 months following&#xD;
             discontinuation of study drug therapy.&#xD;
&#xD;
          5. Subjects must be willing and capable of understanding the purpose and risks of the&#xD;
             study, and must sign a statement of informed consent&#xD;
&#xD;
          6. Subjects with a Creatinine &lt; 2.0 mg/dl at time of transplant&#xD;
&#xD;
        Exclusion Criteria for Study Entry:&#xD;
&#xD;
          1. Allergy to Thymoglobulin-Thymoglobulin is contraindicated in patients with history of&#xD;
             allergy or anaphylaxis to rabbit proteins or to any product excipients, or who have&#xD;
             active acute or chronic infections which contraindicate any additional&#xD;
             immunosuppression&#xD;
&#xD;
          2. Previous organ transplants&#xD;
&#xD;
          3. Patients receiving multiple organs&#xD;
&#xD;
          4. Patients with a BMI higher than 35&#xD;
&#xD;
          5. Patients with PRA ≥ 25%&#xD;
&#xD;
          6. Patients requiring VAD upon completion of transplantation surgery.&#xD;
&#xD;
          7. HIV-1, HTLV-1, chronic Hepatitis B, or chronic Hepatitis C infection&#xD;
&#xD;
          8. Documented or strong suspicion for pre-operative active infection that has not yet&#xD;
             been adequately treated with the recommended course of antimicrobial therapy&#xD;
&#xD;
          9. Presence of any chronic myelosuppressive disease or agent that has resulted in either&#xD;
             chronic leucopenia or chronic thrombocytopenia&#xD;
&#xD;
         10. Active peptic ulcer disease and active GI bleeding&#xD;
&#xD;
         11. Patients who have received within the past 30 days or require concomitant treatment&#xD;
             with other investigational drugs (except for those listed in section 8.6 &quot;Concomitant&#xD;
             treatment&quot;)&#xD;
&#xD;
         12. Patients with a history of AL amyloidosis (TTR amyloids) are permitted&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jon Kobashigawa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kaiser Permanente Los Angeles Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>September 12, 2017</study_first_submitted>
  <study_first_submitted_qc>September 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2017</study_first_posted>
  <last_update_submitted>November 11, 2022</last_update_submitted>
  <last_update_submitted_qc>November 11, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>Jon Kobashigawa</investigator_full_name>
    <investigator_title>Director of Advanced Heart Disease Program</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 31, 2022</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT03292861/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03292861
org study id: ATG Pilot Study
nct id: NCT03292861
lead sponsor: 
collaborator: 
has dmc: Yes
is fda regulated drug: Yes
is fda regulated device: No
This is a randomized, controlled, single center study to evaluate the efficacy of
      Thymoglobulin induction therapy in combination with Mycophenolate Mofetil, tacrolimus, and
      steroids in the prevention of CAV. Approximately half of the patients will be randomized to
      receive a total of 5 doses of Thymoglobulin during the study. The first dose of Thymoglobulin
      will be administered at 1.5 mg/kg via intravenous infusion over 6 hours immediately upon
      arrival to the ICU post-operation (day 1). Subsequent doses of 1.5 mg/kg will be administered
      on days 2, 3, 4, and 5 via IV infusion over 4 hours.

      Mechanistic assays (T-reg cells, Lym subsets, B cell subsets, IL-1b, cytokines, TGFb, IL-21
      to be drawn at Pre-transplant, 3, 6, 12 months post-transplant) will also be performed.

      All patients will be followed and monitored according to standard of care protocols for heart
      transplant recipients at our center.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: Triple (Participant, Care Provider, Investigator)
measure: Percentage of Participants With Composite Efficacy Failure at 12 Months
time frame: 12 Months
description: Composite efficacy failure is defined as development of de novo donor specific antibodies (measured by standardized alloantibody testing by Luminex and control sera, characterizing kinetics, specificities and relative binding strength) and ischemia on endomyocardial biopsy (characterized on biopsy by myocyte necrosis and/or regions of myocyte dropout) at 12 months post-transplant.
measure: Changes in immune cell profiles
time frame: 12 months
description: Correlations between significant changes in immune cell profiles and biomarkers, and their relation to any significant differences in clinical outcomes
measure: Changes in biomarkers
time frame: 12 months
description: Correlations between significant changes in biomarkers and their relation to any significant differences in clinical outcomes
measure: Number of patients who experience rejection
time frame: 12 months
description: Number of patients who experience acute cellular, antibody-mediated, hemodynamic compromise, and any-treated rejection within first 12 months after transplantation/
measure: Number of episodes per patient
time frame: 12 months
description: Number of acute cellular, antibody-mediated, hemodynamic compromise and any-treated rejection episodes per patient within the first 12 months post-transplantation
measure: First rejection by ISHLT biopsy grading scale
time frame: 12 months
description: First acute cellular, antibody-mediated, hemodynamic compromise, and any-treated rejection by the ISHLT biopsy grading scale in the first 12 months post-transplantation
measure: Time to first rejection
time frame: 12 months
description: Time to first acute cellular, antibody-mediated, hemodynamic compromise, and any-treated rejection within the first 12 months
measure: Incidence of primary graft dysfunction (PGD)
time frame: first 24 hours post-transplant
description: The incidence of Primary Graft Dysfunction(PGD) in the first 24 hours post-transplant
measure: Patient and graft survival
time frame: 12 months
description: Patient and graft survival at 12 months post-transplantation
measure: Types of patients with fatal infectious complications
time frame: 12 months
description: The types of patients with fatal infectious complications (especially CMV infection) within the first 12 months post-transplantation
measure: Number of patients with fatal infectious complications
time frame: 12 months
description: The number of patients with fatal infectious complications (especially CMV infection) within the first 12 months post-transplantation
measure: Types of patients with non-fatal infectious complications
time frame: 12 months
description: Types of patients with non-fatal infectious complications (especially CMV infection) within the first 12 months post-transplantation
measure: Number of patients with non-fatal infectious complications
time frame: 12 months
description: Number of patients with non-fatal infectious complications (especially CMV infection) within the first 12 months post-transplantation
measure: Freedom from development of circulating antibodies
time frame: 12 months
description: Freedom from the development of circulating antibodies within the first 12 months post transplantation, where circulating antibodies include donor specific antibodies (DSA), non-specific antibodies, and non-human leukocyte antigen antibodies
measure: Change in coronary maximal intimal thickness
time frame: 12 months
description: Change in coronary maximal intimal thickness at matched sites by intravascular ultrasound at 12 months
measure: Change in coronary intimal area
time frame: 12 months
description: Change in coronary intimal area at matched sites by intravascular ultrasound at 12 months
measure: Change in coronary intimal volume
time frame: 12 months
description: Change in coronary intimal volume at matched sites by intravascular ultrasound at 12 months
measure: Change in coronary vessel area
time frame: 12 months
description: Change in coronary vessel area at matched sites by intravascular ultrasound at 12 months
measure: Change in coronary intimal index
time frame: 12 months
description: Change in coronary intimal index at matched sites by intravascular ultrasound at 12 months
measure: Change in coronary percent atheroma volume
time frame: 12 months
description: Change in coronary percent atheroma volume at matched sites by intravascular ultrasound at 12 months
measure: Maintenance doses of mycophenolate mofetil, tacrolimus, sirolimus, and dose of corticosteroids
time frame: 12 months
description: Maintenance doses of mycophenolate mofetil, tacrolimus, sirolimus, and cumulative dose of corticosteroids at 12 months post-transplantation
measure: Number of hospital days per patient
time frame: 3 months, 6 months, 12 months
description: Number of hospital days per patient, both during the transplant period and during the post-transplant period at 3 months, 6 months, and 1 year
measure: Number of patients requiring hospitalization
time frame: 3 months, 6 months, 12 months
description: Number of patients requiring hospitalization by 3 months, by 6 months, or by 1 year post-transplantation
measure: Death/Re-transplant
time frame: 12 months
description: To describe between treatment groups the incidence of the composite primary endpoint of death/re-transplant at 12 months post-transplantation
measure: Hemodynamic compromise rejection
time frame: 12 months
description: To describe between treatment groups the incidence of the composite primary endpoint of hemodynamic compromise rejection at 12 months post-transplantation. This is an ejection fraction of ≤ 30% or a 0.20 absolute decrease from baseline, and the need for inotropic agents OR a fractional shortening ≤ 20% or a 25% decrease from baseline, and the need for inotropic agents PLUS need for inotropic agents due to a Cardiac Index (CI) < 2.0 L/min/m2 or a 25% decrease from baseline
measure: Graft dysfunction
time frame: 12 months
description: To describe between treatment groups the incidence of the composite primary endpoint of graft dysfunction (ejection fraction less than or equal to 40% by echocardiography)at 12 months post-transplantation
measure: Cellular rejection
time frame: 12 months
description: To describe between treatment groups the incidence of the composite primary endpoint of biopsy proven cellular rejection ≥2R at 12 months post-transplantation
measure: Antibody mediated rejected
time frame: 12 months
description: To describe between treatment groups the incidence of the composite primary endpoint of biopsy proven antibody mediated rejection ≥AMR1 at 12 months post-transplantation
measure: Cardiac Allograft Vasculopathy (CAV)
time frame: 12 months
description: To describe between treatment groups the incidence of cardiac allograft vasculopathy (CAV) (defined as a change ≥0.5mm in maximal intimal thickness (MIT) of the coronary arteries by intravascular ultrasound at 12 months as compared to baseline)
measure: Any treated rejection
time frame: 12 months
description: To describe between treatment groups any treated rejection at 12 months
arm group label: Thymoglobulin®
arm group type: Active Comparator
description: Thymoglobulin® (Genzyme) [rabbit anti-thymocyte globulin (ATG)] is a purified pasteurized, gamma immune globulin, obtained by immunization of rabbits with human thymocytes. This immunosuppressive product contains polyclonal cytotoxic antibodies directed against antigens expressed on human T-lymphocytes. Approximately half of the patients will be randomized to receive a total of 5 doses of Thymoglobulin during the study. The first dose of Thymoglobulin will be administered at 1.5 mg/kg via intravenous infusion over 6 hours immediately upon arrival to the ICU post-operation (day 1). Subsequent doses of 1.5 mg/kg will be administered on days 2, 3, 4, and 5 via IV infusion over 4 hours.
In addition, there will be maintenance doses of mycophenolate mofetil, tacrolimus, sirolimus, and cumulative dose of corticosteroids at 12 months post-transplantation
arm group label: No induction therapy
arm group type: No Intervention
description: Patients qualifying for the study will be randomized before the transplantation surgery in a 1:1 ratio to either Thymoglobulin® or no treatment.
intervention type: Drug
intervention name: Thymoglobulin
description: Approximately half of the patients will be randomized to receive a total of 5 doses of Thymoglobulin during the study. The first dose of Thymoglobulin will be administered at 1.5 mg/kg via intravenous infusion over 8 hours immediately upon arrival to the ICU post-operation (day 1). Subsequent doses of 1.5 mg/kg will be administered on days 2, 3, 4, and 5 via IV infusion over 4-8 hours.
arm group label: Thymoglobulin®
intervention type: Drug
intervention name: Mycophenolate Mofetil
description: 3.0 grams divided bid begun post-transplant, either IV or po as tolerated by patient. Initial dose must be given within 24 hours post-transplant. Dosing will be titrated based on recipient's body size and any adverse side effects
arm group label: Thymoglobulin®
intervention type: Drug
intervention name: Tacrolimus
description: Doses of 1-4 mg bid either IV or po will be prescribed to achieve a target trough level of 10-15 ng/mL before post-operative day number 5. Target trough levels are 10-15 ng/mL for post-operative days #1-30, 8-12ng/mL days#31-60 and 5-10 ng/mL thereafter.
arm group label: Thymoglobulin®
intervention type: Drug
intervention name: Sirolimus
description: Maintenance doses of sirolimus at 12 months post-transplantation
arm group label: Thymoglobulin®
intervention type: Drug
intervention name: Corticosteroids
description: 125 mg IV methylprednisolone immediately post-operatively x 3 doses q12hrs, then switching to oral prednisone at 1.0 mg/kg/day po divided into bid doses that are rounded off to the next higher 5 mg increment. For example, a 76 kg person would should be dosed at 38 mg po bid, which rounded off to the next 5 mg increment would be 40 mg po bid. (Equivalent dosing via an alternative route may be used if pos not tolerated or contraindicated). Prednisone will be tapered by 10 mg qd until the dose of 10 mg po bid is reached.
arm group label: Thymoglobulin®
criteria: 
gender: All
minimum age: 18 Years
maximum age: 70 Years
healthy volunteers: No
last name: Jon Kobashigawa, MD
role: Principal Investigator
affiliation: Director
facility: 
facility: 
country: United States
responsible party type: Principal Investigator
investigator affiliation: Cedars-Sinai Medical Center
investigator full name: Jon Kobashigawa
investigator title: Director of Advanced Heart Disease Program
mesh term: Mycophenolic Acid
mesh term: Sirolimus
mesh term: Tacrolimus
mesh term: Thymoglobulin
provided document: 